EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies


Clinical Gastroenterology and Hepatology 11(3): 224-31.E1-5
Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies
The response to injury is one of wound healing and fibrogenesis, which ultimately leads to fibrosis. The fibrogenic response to injury is a generalized one across virtually all organ systems. In the liver, the injury response, typically occuring over a prolonged period of time, leads to cirrhosis (although it should be pointed out that not all patients with liver injury develop cirrhosis). The fact that many different diseases result in cirrhosis suggests a common pathogenesis. The study of hepatic fibrogenesis over the past 2 decades has been remarkably active, leading to a considerable understanding of this process. It has been clearly demonstrated that the hepatic stellate cell is a central component in the fibrogenic process. It has also been recognized that other effector cells are important in the fibrogenic process, including resident fibroblasts, bone marrow derived cells, fibrocytes, and even perhaps cells derived from epithelial cells (i.e., through epithelial to mesenchymal transition or EMT). A key aspect of the biology of fibrogenesis is that the fibrogenic process is dynamic; thus, even advanced fibrosis (or cirrhosis) is reversible. Together, an understanding of the cellular basis for liver fibrogenesis, along with multiple aspects of the basic pathogenesis of fibrosis, have highlighted many exciting potential therapeutic opportunities. Thus, while the most effective anti-fibrotic therapy is treatment of the underlying disease, in situations in which this not possible, specific anti-fibrotic therapy is likely to not only become feasible, but will soon become a reality. The goal of this review is to highlight the mechanisms underlying fibrogenesis that may be translated into future anti-fibrotic therapies and to review the current state of clinical development.

(PDF same-day service: $19.90)

Accession: 036708067

PMID: 23305825

DOI: 10.1016/j.cgh.2013.01.005



Related references

Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies. Clinics in Liver Disease 12(4): Xiii-Xxiv, 2008

Idiopathic interstitial pneumonias: translating our current understanding into novel therapies. Experimental Lung Research 31 Suppl 1: 41-46, 2006

Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 181(6): 532-533, 2010

Liver Fibrosis: From Pathogenesis to Novel Therapies. Digestive Diseases 34(4): 410-422, 2016

Comments on the pathogenesis of Behçet's disease. A key to understanding new therapies?. Der Ophthalmologe 109(6): 563-567, 2012

Recent understanding of IBD pathogenesis: implications for future therapies. Inflammatory Bowel Diseases 12(11): 1068-1083, 2006

New therapies for hepatic fibrosis. Clinics and Research in Hepatology and Gastroenterology 39 Suppl 1: S75-S79, 2016

Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clinical Biochemistry 47(7-8): 539-546, 2014

Hepatic Fibrosis: Emerging Therapies. Digestive Diseases 33(4): 504-507, 2016

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Review of Respiratory Medicine 9(5): 633-654, 2016